biote Corp. (BTMD)
| Market Cap | 83.19M -31.7% |
| Revenue (ttm) | 188.16M -5.6% |
| Net Income | 15.60M -25.8% |
| EPS | 0.43 -28.5% |
| Shares Out | 35.55M |
| PE Ratio | 5.46 |
| Forward PE | 10.72 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 76,976 |
| Open | 2.380 |
| Previous Close | 2.360 |
| Day's Range | 2.330 - 2.380 |
| 52-Week Range | 1.270 - 4.750 |
| Beta | 1.66 |
| Analysts | Strong Buy |
| Price Target | 2.99 (+27.78%) |
| Earnings Date | May 6, 2026 |
About BTMD
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice m... [Read more]
Financial Performance
In 2025, biote's revenue was $192.22 million, a decrease of -2.52% compared to the previous year's $197.19 million. Earnings were $27.05 million, an increase of 756.67%.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for BTMD stock is "Strong Buy." The 12-month stock price target is $2.99, which is an increase of 27.78% from the latest price.
News
Biote appoints Bajaj as Chief Medical Officer
Biote (BTMD) announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Bajaj joins Biote following senior leadership roles within NYC Health +…
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr. Baja...
Biote announces Christensen to step down as CEO, Peterson named interim CEO
Biote (BTMD) announced that Bob Peterson, Chief Financial Officer and Chief Business Officer, has been named Interim Chief Executive Officer and Director, effective June 8, 2026. Bret Christensen is s...
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...
Biote reports Q1 EPS 6c, one estimate 8c
Reports Q1 revenue $44.9M, consensus $46.0M. “During the first quarter of 2026, we continued to advance our strategic priorities and remained focused on our key objective of restoring sustainable proc...
Biote sees FY26 revenue over $190M, consensus $191.7M
16:56 EDT Biote (BTMD) sees FY26 revenue over $190M, consensus $191.7M
biote Earnings Call Transcript: Q1 2026
Revenue declined 8.3% year-over-year due to a voluntary recall, impacting both sales and margins, but dietary supplement revenue grew 19.1%. Management expects supply normalization and sales force expansion to drive a return to growth in the second half of 2026.
biote Earnings release: Q1 2026
biote released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
biote Quarterly report: Q1 2026
biote has published its Q1 2026 quarterly earnings report on May 6, 2026.
Biote Reports First Quarter 2026 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...
Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our Practi...
Biote price target lowered to $4 from $5 at Truist
Truist analyst Les Sulewski lowered the firm’s price target on Biote (BTMD) to $4 from $5 and keeps a Buy rating on the shares as part of a broader research…
SunTx Capital Partners' Portfolio Company, Suncrete, and Haymaker Acquisition Corp. 4, Successfully Complete Business Combination
Combined Company to Trade as Suncrete Under Ticker "RMIX" Suncrete to Ring the Nasdaq Stock Market Closing Bell DALLAS, April 8, 2026 /PRNewswire/ -- Concrete Partners Holding, LLC ("CPH"), a ready-m...
biote Proxy statement: Proxy filing
biote filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
biote Proxy statement: Proxy filing
biote filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.
Suncrete and Haymaker Acquisition Corp. 4 Announce Upsizing of Private Placement from $105.5 Million to $167.1 Million and Extend Stockholder Redemption Deadline
DALLAS, March 27, 2026 /PRNewswire/ -- Concrete Partners Holding, LLC ("Suncrete" or the "Company"), a ready-mix concrete logistics and distribution platform strategically located in Oklahoma and Arka...
Suncrete and Haymaker Acquisition Corp. 4 Announce Entering Into Non-Redemption Agreements with Certain Institutional Investors
DALLAS, March 25, 2026 /PRNewswire/ -- Concrete Partners Holding, LLC ("Suncrete" or the "Company"), a ready-mix concrete logistics and distribution platform strategically located in Oklahoma and Arka...
Biote price target lowered to $2 from $3 at B. Riley
B. Riley lowered the firm’s price target on Biote (BTMD) to $2 from $3 and keeps a Neutral rating on the shares following the Q4 earnings report. While progress is…
Biote price target lowered to $3 from $4.50 at Roth Capital
Roth Capital lowered the firm’s price target on Biote (BTMD) to $3 from $4.50 and keeps a Buy rating on the shares. The company’s Q4 results and 2026 guide showed…
Biote price target lowered to $2.50 from $3 at TD Cowen
TD Cowen lowered the firm’s price target on Biote (BTMD) to $2.50 from $3 and keeps a Buy rating on the shares. The firm said 4Q25 sales and& EBITDA beat…
biote Earnings Call Transcript: Q4 2025
Revenue declined in Q4 2025 due to higher clinic attrition and a voluntary recall, but dietary supplement sales grew strongly. Investments in sales and technology are expected to drive a return to procedure revenue growth in the second half of 2026, with full-year revenue forecast above $190M.
biote Annual report: Q4 2025
biote has published its Q4 2025 annual report on March 11, 2026.
biote Earnings release: Q4 2025
biote released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
Biote reports Q4 EPS 6c, one estimate 10c
Reports Q4 revenue $46.4M, consensus $45.8M. “Over the past twelve months, Biote (BTMD) has focused on our strategic priorities which are designed to drive sustainable profitable growth and create lon...
Biote Reports Fourth Quarter and Full Year 2025 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announce...